While Mylan (MYL - Get Report) has consistently made headlines for controversy over the pricing of its EpiPen, an auto-injector used to treat anaphylaxis and severe food allergies, there's more to the pricing of its competitor than meets the eye. Released today, Kaleo's Auvi-Q will cost insurers 9 times more than the Epipen. In response, Express Scripts (ESRX) , UnitedHealth Group (UNH - Get Report) and Cigna (CI - Get Report) will not cover the device.

This article was written by a staff member of TheStreet.